Veroscience Drug Patent Portfolio
Veroscience owns 1 orange book drug protected by 22 US patents Given below is the list of Veroscience's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10688094 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US11000522 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US11666567 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US8431155 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US8613947 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US9192576 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US9522117 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US9700555 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US9993474 | Bromocriptine formulations | 30 Apr, 2032 | Active |
| US10688155 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders | 07 Jun, 2030 | Active |
| US8877708 | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders | 07 Jun, 2030 | Active |
| US9352025 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders | 07 Jun, 2030 | Active |
| US9895422 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders | 07 Jun, 2030 | Active |
| US7888310 | Methods of identifying responders to dopamine agonist therapy | 25 Jul, 2023 | Expired |
| US8137992 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof | 25 Jul, 2023 | Expired |
| US8137993 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof | 25 Jul, 2023 | Expired |
| US8137994 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof | 25 Jul, 2023 | Expired |
| US5716957 | Method for modifying and resetting the bloodstream prolactin levels of a human subject | 10 Feb, 2015 | Expired |
| US5679685 | Accelerated release composition containing bromocriptine | 21 Oct, 2014 | Expired |
| US5468755 | Therapeutic process for the treatment of the pathologies of Type II diabetes | 21 Nov, 2012 | Expired |
| US5756513 | Therapeutic process for the treatment of the pathologies of type II diabetes | 21 Nov, 2012 | Expired |
| US5866584 | Therapeutic process for the treatment of the pathologies of type II diabetes | 21 Nov, 2012 | Expired |
Latest Legal Activities on Veroscience's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Veroscience.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Dec, 2023 | US10688094 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Dec, 2023 | US10688155 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8137993 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8137992 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2023 | US8137994 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 May, 2023 | US9192576 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Oct, 2022 | US7888310 |
| 11.5 yr surcharge- late pmt w/in 6 mo, Large Entity | 10 Oct, 2022 | US7888310 |
|
Maintenance Fee Reminder Mailed
Critical
| 03 Oct, 2022 | US7888310 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Large Entity | 13 May, 2022 | US8877708 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 May, 2022 | US8877708 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2021 | US9993474 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Aug, 2021 | US9895422 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 24 Jun, 2021 | US8613947 |
| Post Issue Communication - Certificate of Correction | 16 Jun, 2021 | US11000522 |
Veroscience's Family Patents
Veroscience drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 49.0% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Veroscience Drug List
Given below is the complete list of Veroscience's drugs and the patents protecting them.
1. Cycloset
Cycloset is protected by 22 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10688094 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US11000522 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US11666567 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US8431155 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US8613947 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US9192576 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US9522117 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US9700555 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US9993474 | Bromocriptine formulations |
30 Apr, 2032
(6 years from now)
| Active |
| US10688155 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
07 Jun, 2030
(4 years from now)
| Active |
| US8877708 | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
07 Jun, 2030
(4 years from now)
| Active |
| US9352025 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
07 Jun, 2030
(4 years from now)
| Active |
| US9895422 | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
07 Jun, 2030
(4 years from now)
| Active |
| US7888310 | Methods of identifying responders to dopamine agonist therapy |
25 Jul, 2023
(2 years ago)
| Expired |
| US8137992 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
25 Jul, 2023
(2 years ago)
| Expired |
| US8137993 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
25 Jul, 2023
(2 years ago)
| Expired |
| US8137994 | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
25 Jul, 2023
(2 years ago)
| Expired |
| US5716957 | Method for modifying and resetting the bloodstream prolactin levels of a human subject |
10 Feb, 2015
(10 years ago)
| Expired |
| US5679685 | Accelerated release composition containing bromocriptine |
21 Oct, 2014
(11 years ago)
| Expired |
| US5468755 | Therapeutic process for the treatment of the pathologies of Type II diabetes |
21 Nov, 2012
(12 years ago)
| Expired |
| US5756513 | Therapeutic process for the treatment of the pathologies of type II diabetes |
21 Nov, 2012
(12 years ago)
| Expired |
| US5866584 | Therapeutic process for the treatment of the pathologies of type II diabetes |
21 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cycloset's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List